🔬
Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?
active
analysis
Created: 2026-04-26T15:50:49
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: SDA-2026-04-26-gap-debate-20260417-03313
🔬 Analysis Details
Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?
completed
neurodegeneration
🧪 7 hypotheses
📓 0 notebooks
$0.00
Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | analyses |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.